查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1696299

全球即时诊断市场 - 2025 至 2033 年

Global Point of Care Diagnostics Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球即时诊断市场规模达到 154.6 亿美元，预计到 2033 年将达到 326.3 亿美元，在 2025-2033 年预测期内的复合年增长率为 8.7%。

即时诊断是指在病患照护地点或附近而不是在集中实验室或医院环境中进行的医疗诊断测试过程。这些测试旨在提供快速可靠的结果，帮助医疗保健提供者就患者的诊断和治疗做出快速、明智的决定。目标是实现立即决策，而无需患者等待结果或前往另一个地点进行检测。

即时诊断是一个快速发展的领域，它使医疗保健专业人员和患者能够在护理地点或附近进行诊断测试。随着应用和创新的不断增加，即时诊断正在透过使诊断更快、更方便、更有效率来改变医疗保健服务。

市场动态：

驱动因素与约束因素

即时诊断技术不断进步

即时诊断（POC）技术的不断进步是全球 POC 诊断市场发展的主要驱动力。分子诊断、微流体和生物感测器等新技术提高了即时诊断设备的准确性和速度。这些进步使得测试能够快速完成，通常只需 30 分钟，而且成本较低。

例如，2024 年 1 月，3EO Health 利用 3TR 技术进行 COVID-19 测试获得了 FDA 紧急使用授权 (EUA)。 3TR 技术无需样品製备、昂贵的耗材和复杂的设备，创造了一种全新类型的「高效能」即时分子检测。高效率的定义是低成本、易于使用的分子检测，每次检测费用低于 20 美元，且无需製备样品。

人工智慧 (AI) 在解释测试结果方面发挥越来越重要的作用，可以提供更快、更准确的决策。人工智慧的即时诊断可以分析诊断资料并帮助临床医生以低成本做出更快、更准确的诊断。例如，2025 年 2 月，Avitia 推出了一个由人工智慧驱动的快速和即时癌症检测平台。借助 Avitia 的平台，实验室和临床医生现在可以进行先进的分子检测。这项技术将使医疗团队能够准确地获得癌症见解并以更低的成本更快地开始治疗患者。

此外，2024 年 5 月，MolBio 宣布正在研究血液学、癌症、抗菌素抗药性 (AMR)、下一代定序 (NGS)、综合征检测等领域的许多开创性的即时诊断技术。该公司正在开发支援人工智慧 (AI) 的即时诊断测试 TruSight，用于各种血液学应用，包括全血球计数 (CBC)。该平台最终还可用于巴氏抹片检查、疟原虫、精子数、镰状细胞疾病、地中海贫血等。

连接和数据集成问题

广泛采用即时诊断技术的主要障碍之一是设备、医疗 IT 系统和电子健康记录之间缺乏互通性。在许多医疗保健环境中，诊断设备、电子健康系统和患者资料平台并未集成，因此难以即时整合和存取患者资料。

由于即时诊断设备经常传输敏感的健康资料，因此维护这些资讯的安全性和隐私至关重要。资料整合不佳可能会使患者资讯暴露于未经授权的访问，使得医疗保健提供者难以确保遵守资料保护法规（例如美国的 HIPAA 或欧洲的 GDPR）。

例如，根据《HIPAA杂誌》报道，2023 年 8 月，共报告了 2,300 万份医疗记录被洩露。在过去的 12 个月中，平均每月有 9,989,003 份医疗记录被洩露。截至 2024 年 8 月 31 日的一年中，已发生 491 起涉及 500 笔或更多记录的资料外洩事件，已知外洩记录至少有 58,668,002 则。与连接和资料整合相关的问题，例如互通性挑战、资料安全问题、手动资料输入和云端储存效率低下，都是阻碍市场成长的重大障碍。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 产品片段
  • 技术片段
  • 按应用程式截取的程式码片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第 3 章：动态

  • 影响因素
    • 驱动程式
      • 即时诊断技术不断进步
      • 人口老化和慢性疾病加剧
    • 限制
      • 连接和数据集成问题
      • 来自替代诊断技术的竞争
    • 机会
      • 扩大居家检测范围
      • 数位与行动健康融合的进步
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 5 章：即时诊断市场（依产品划分）

  • 传染病检测产品
  • 血糖产品
  • 血气和电解质产品
  • 血液学检测产品
  • 尿液分析产品
  • 妊娠和生育测试产品
  • 肿瘤/癌症分析产品
  • 滥用药物产品
  • 其他的

第 6 章：即时诊断市场（按技术划分）

  • 横向流动侦测
  • 免疫测定
  • 分子诊断
  • 微流体
  • 其他的

第 7 章：即时诊断市场（按应用）

  • 传染病
  • 血液学
  • 心臟病学
  • 内分泌学
  • 肿瘤学
  • 药物检测
  • 神经病学
  • 其他的

第 8 章：即时诊断市场（以最终用户划分）

  • 医院和诊所
  • 诊断实验室
  • 门诊手术中心 (ASC)
  • 家庭护理设置

第 9 章：即时诊断市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 阿根廷
    • 拉丁美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第 11 章：公司简介

  • BD
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • QuidelOrtho Corporation
  • QIAGEN
  • Trinity Biotech plc.
  • BioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Abbott Laboratories
  • Danaher Corporation
  • SEKISUI MEDICAL CO., LTD.

第 12 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 13 章：附录

简介目录
Product Code: MD1063

The global point of care diagnostics market reached US$ 15.46 billion in 2024 and is expected to reach US$ 32.63 billion by 2033, growing at a CAGR of 8.7 % during the forecast period of 2025-2033.

Point-of-care diagnostics refers to a medical diagnostic testing process that takes place at or near the site of patient care, rather than in a centralized laboratory or hospital setting. These tests are designed to deliver rapid and reliable results that help healthcare providers make quick, informed decisions regarding patient diagnosis and treatment. The goal is to enable immediate decision-making without the need for a patient to wait for results or travel to another location for testing.

Point-of-care diagnostics is a rapidly advancing field that enables healthcare professionals and patients to perform diagnostic tests at or near the site of care. With growing adoption and innovations, point-of-care diagnostics is transforming healthcare delivery by making diagnostics faster, more accessible and more efficient.

Market Dynamics: Drivers & Restraints

Rising Advancements in Point-of-Care Diagnostics

Rising advancements in point-of-care (POC) diagnostics are a key driver of the global POC diagnostics market. New technologies like molecular diagnostics, microfluidics and biosensors have improved the accuracy and speed of point-of-care diagnostic devices. These advancements allow tests to be performed rapidly, often in less than 30 minutes at a low cost.

For instance, in January 2024, 3EO Health received FDA Emergency Use Authorization (EUA) for its COVID-19 test utilizing 3TR technology. 3TR technology eliminates the need for sample preparation, expensive consumables and complex equipment, creating a new category of "high efficiency" point-of-care molecular testing. High efficiency is defined as low-cost, easy-to-use molecular testing under $20 per test with no sample preparation required.

Artificial Intelligence (AI) is playing an increasing role in the interpretation of test results, offering quicker and more accurate decision-making. AI-powered point-of-care diagnostics can analyze diagnostic data and help clinicians make faster, more accurate diagnoses at low costs. For instance, in February 2025, Avitia launched an AI-powered platform for rapid & point-of-care cancer testing. With Avitia's platform, laboratories and clinicians now have access to advanced molecular testing. This technology will allow a healthcare team to accurately obtain cancer insights and begin treating patients faster all at reduced costs.

Also, in May 2024, MolBio announced that it is working on many pathbreaking point-of-care technologies in the areas of hematology, cancer, anti-microbial resistance (AMR), next-generation sequencing (NGS), syndromic testing, etc. The company is developing artificial intelligence (AI)-enabled point-of-care test TruSight for various hematology applications, including complete blood count (CBC). This platform could also be eventually used for PAP smears, malaria parasites, sperm counting, sickle cell disease, thalassemia, etc.

Connectivity & Data Integration Issues

One of the primary barriers to the widespread adoption of point-of-care diagnostic technologies is the lack of interoperability between devices, healthcare IT systems and electronic health records. In many healthcare environments, diagnostic devices, electronic health systems and patient data platforms are not integrated, making it difficult to consolidate and access patient data in real-time.

As point-of-care diagnostic devices often transmit sensitive health data, maintaining the security and privacy of this information is critical. Poor data integration can expose patient information to unauthorized access, making it difficult for healthcare providers to ensure compliance with data protection regulations (such as HIPAA in the U.S. or GDPR in Europe).

For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records were reported. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The issues related to connectivity and data integration, such as interoperability challenges, data security concerns, manual data entry and cloud storage inefficiencies are significant barriers to the growth of the market.

Segment Analysis

The global point of care diagnostics market is segmented based on product, technology, application, end-user, and region.

Product:

The infectious disease testing products segment in the product is expected to dominate the global point of care diagnostics market with the highest market share

Infectious disease test products are diagnostic tools used to detect pathogens like bacteria or viruses in the body. They are crucial in identifying and controlling the spread of infectious diseases. Manufacturers offer various types of products, each tailored to detect specific pathogens or markers associated with specific diseases. Rapid tests provide quick results, often within minutes, and are commonly used for point-of-care testing.

Moreover, diagnostic testing capabilities for infectious diseases like influenza, SARS-CoV-2, Clostridium difficile, HIV, Group A streptococcus, STIs, and Lyme disease have significantly improved over the past few years due to significant launches, product innovations, and other various factors. For instance, in February 2023, Thermo Fisher Scientific announced that its Applied Biosystems TaqPath PCR products for infectious diseases like MTB MDR, MT B, HBV, HCV, HIV, and HLA B27 have received licensing rights from the Central Drugs Standard Control Organization (CDSCO). The products will be manufactured in India in association with Mylab Discove1Y Solutions.

Also, growth for rapid and accurate diagnostics of infectious diseases, driven by early detection, decentralized testing, and antimicrobial resistance, is expanding. Government initiatives to improve diagnostic capabilities, especially in low- and middle-income countries, further support market expansion. These factors have solidified the segment's position in the global point of care diagnostics market.

Geographical Analysis

North America is expected to hold a significant position in the global point of care diagnostics market with the highest market share

North America, particularly the United States and Canada, holds a dominant position in the global POC diagnostics market. This market includes a wide range of diagnostic products such as blood glucose monitors, cardiac markers, pregnancy tests, infectious disease testing, and cholesterol testing.

The North American market is well-established with a high demand for diagnostic testing across various healthcare settings, including hospitals, clinics, urgent care centers, and even homecare environments. The increasing incidence of chronic diseases such as diabetes, cardiovascular diseases, respiratory disorders, and cancer is one of the primary drivers of the POC diagnostics market in North America. These conditions require regular monitoring and testing, which is facilitated by POC devices.

Key players in the region are receiving regulatory approvals and launching their products in the region. For instance, in January 2025, Roche received FDA clearance with a CLIA waiver for its cobas Liat molecular tests designed to diagnose sexually transmitted infections (STIs) at the point of care. Roche's cobas Liat molecular tests have met the regulatory standards for safety and effectiveness in the U.S. market. This is a significant milestone, as it ensures that the tests can be used legally and widely in healthcare settings. Thus, the above factors are consolidating the region's position as a dominant force in the global point of care diagnostics market.

Competitive Landscape

The major global players in the point of care diagnostics market include BD, QuidelOrtho Corporation, QIAGEN, Trinity Biotech plc., BioMerieux SA, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Abbott Laboratories, Danaher Corporation, and SEKISUI MEDICAL CO., LTD. among others.

Key Developments

  • In February 2025, Avitia launched an AI-powered platform for rapid & point-of-care cancer testing. With Avitia's platform, laboratories and clinicians now have access to advanced molecular testing. This technology will allow a healthcare team to accurately obtain cancer insights and begin treating patients faster all at reduced costs.
  • In January 2025, Roche announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver for its cobas liat sexually transmitted infection (STI) multiplex assay panels at the point of care. These panels, including tests for chlamydia and gonorrhea (CT/NG) and chlamydia, gonorrhea, and Mycoplasma genitalium (CT/NG/MG), enable clinicians to diagnose and differentiate between multiple STIs with a single sample.
  • In May 2024, MolBio announced that it is working on many pathbreaking point-of-care technologies in hematology, cancer, anti-microbial resistance (AMR), next-generation sequencing (NGS), syndromic testing, etc. The company is developing artificial intelligence (AI)-enabled point-of-care test TruSight for various hematology applications, including complete blood count (CBC). This platform could also be used for PAP smears, malaria parasites, sperm counting, sickle cell disease, thalassemia, etc.
  • In January 2024, 3EO Health received FDA Emergency Use Authorization (EUA) for its COVID-19 test utilizing 3TR technology. 3TR technology eliminates the need for sample preparation, expensive consumables and complex equipment, creating a new category of "high efficiency" point-of-care molecular testing. High efficiency is defined as low-cost, easy-to-use molecular testing under $20 per test with no sample preparation required.
  • In April 2024, Roche Diagnostics India announced the launch of its point-of-care NT-proBNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure (HF). This breakthrough innovation is designed to bring testing closer to clinics and revolutionize patient care. The claim extension of the NT-proBNP biomarker, available exclusively on the cobas h 232 system, aims to provide faster, more efficient diagnosis and management of HF in patients with type 2 diabetes (T2D).

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global point of care diagnostics market report delivers a detailed analysis with 70+ key tables, more than 70+ visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product
  • 2.4. Snippet by Technology
  • 2.5. Snippet by Application
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in Point-of-Care Diagnostics
      • 3.1.1.2. Rising Aging Population and Chronic Diseases
    • 3.1.2. Restraints
      • 3.1.2.1. Connectivity & Data Integration Issues
      • 3.1.2.2. Competition from Alternative Diagnostic Technologies
    • 3.1.3. Opportunity
      • 3.1.3.1. Expansion of Home-Based Testing
      • 3.1.3.2. Advancements in Digital and Mobile Health Integration
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Point of Care Diagnostics Market, By Product

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
    • 5.1.2. Market Attractiveness Index By Product
  • 5.2. Infectious Disease Testing Products*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Blood Glucose Products
  • 5.4. Blood Gas & Electrolyte Products
  • 5.5. Hematology Testing Products
  • 5.6. Urinalysis Products
  • 5.7. Pregnancy and Fertility Testing Products
  • 5.8. Tumor/Cancer Profiling Products
  • 5.9. Drug-of-Abuse Products
  • 5.10. Others

6. Point of Care Diagnostics Market, By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index By Technology
  • 6.2. Lateral Flow Assays*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Immunoassays
  • 6.4. Molecular Diagnostics
  • 6.5. Microfluidics
  • 6.6. Others

7. Point of Care Diagnostics Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index By Application
  • 7.2. Infectious Diseases*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Hematology
  • 7.4. Cardiology
  • 7.5. Endocrinology
  • 7.6. Oncology
  • 7.7. Drug Testing
  • 7.8. Neurology
  • 7.9. Others

8. Point of Care Diagnostics Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals & Clinics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diagnostic Laboratories
  • 8.4. Ambulatory Surgery Centers (ASCs)
  • 8.5. Home Care Settings

9. Point of Care Diagnostics Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Mexico
      • 9.4.7.2. Brazil
      • 9.4.7.3. Argentina
      • 9.4.7.4. Rest of Latin America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. BD*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals, etc.
    • 11.1.5. SWOT Analysis
  • 11.2. QuidelOrtho Corporation
  • 11.3. QIAGEN
  • 11.4. Trinity Biotech plc.
  • 11.5. BioMerieux SA
  • 11.6. F. Hoffmann-La Roche Ltd
  • 11.7. Siemens Healthineers AG
  • 11.8. Abbott Laboratories
  • 11.9. Danaher Corporation
  • 11.10. SEKISUI MEDICAL CO., LTD.

LIST NOT EXHAUSTIVE

12. Assumptions and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us